$AGRX News
Last published 2y ago
- 2y agoAGRXAgile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.GlobeNewswireAgile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per
- 2y agoAGRXENVHTLFSPR+1Kuehn Law Encourages AGRX, SPR, ENV, and UMBF Investors to Contact Law FirmGlobeNewswireNEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoAGRXALLGHCPSPRKuehn Law Encourages AGRX, SPR, HCP, and ALLG Investors to Contact Law FirmGlobeNewswireNEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoAGRXAgile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.GlobeNewswireAgile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per
- 2y agoAGRXAgile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAGRXAgile Therapeutics Announces Delisting from NasdaqGlobeNewswirePRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that the Company has received a
- 2y agoAGRXCorrection - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024GlobeNewswirePRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before
- 2y agoAGRXAgile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024GlobeNewswirePRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before
- 2y agoAGRXAgile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan ExecutionGlobeNewswirePRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile" or the "Company"), a women's healthcare company, today announced that it has paid-off the remainder of its debt
- 2y agoAGRXGSKGlobal Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits ResearchGlobeNewswireNew York, United States, March 12, 2024 (GLOBE NEWSWIRE) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases (STDs), the transmission of sexually
- 2y agoAGRXAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross ProceedsGlobeNewswirePRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the entry into a definitive agreement
- 2y agoAGRXAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance UpdateGlobeNewswireCompany Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20
- 2y agoAGRXThe Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without CostGlobeNewswireImplementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to
- 2y agoAGRXAgile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage RequirementGlobeNewswireThe Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration
- 2y agoAGRXAgile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024ACCESS NewswirePRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. , the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong
- 3y agoAGRXAgile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireTwirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin
- 3y agoAGRXAgile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023GlobeNewswireLive Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report third
- 3y agoAGRXAgile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced the granting of a previously disclosed inducement award to the Company's newly
- 3y agoAGRXAgile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim GroupACCESS NewswirePRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of
- 3y agoAGRXAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswirePRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief
- 3y agoAGRXAgile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second QuarterACCESS NewswirePRINCETON, NJ / ACCESSWIRE / August 17, 2023 / On August 9, Agile Therapeutics released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control
- 3y agoAGRXAgile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023GlobeNewswirePRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open
- 3y agoAGRXThis Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With AfaxysACCESS NewswirePRINCETON, NJ / ACCESSWIRE / July 19, 2023 / Agile Therapeutics, Inc.'s partnership with Afaxys Pharma is expected to play a key role in propelling the women's healthcare company toward its $25-$30 million
- 3y agoAGRXAgile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of WomenACCESS NewswirePRINCETON, NJ / ACCESSWIRE / July 18, 2023 / This month, Agile Therapeutics, Inc. announced partnerships with FPA Women's Health and vitaCare Prescription Services that will expand access to Twirla®
- 3y agoAGRXAgile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive CoverageACCESS NewswirePRINCETON, NJ / ACCESSWIRE / July 11, 2023 / - In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. It directs the Secretaries
- 3y agoAGRXH.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control PatchACCESS NewswirePRINCETON, NJ / ACCESSWIRE / July 5, 2023 / H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. this month, setting a price target of $12 per share. The $12 price target is based
- 3y agoAGRXThis Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023ACCESS NewswireAgile Says Growing Demand For Twirla transdermal system Is Helping It Stay On Track to Hit $25-$30 Million Net RevenuePRINCETON, NJ / ACCESSWIRE / July 3, 2023 / Agile Therapeutics
- 3y agoAGRXAgile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?ACCESS NewswirePRINCETON, NJ / ACCESSWIRE / June 30, 2023 / Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control - such as the pill and condoms -
- 3y agoAGRXThe Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of CareACCESS NewswirePRINCETON, NJ / ACCESSWIRE / June 28, 2023 / The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to
- 3y agoAGRXAgile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse MembersGlobeNewswireTwirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities in all 50 states
- 3y agoAGRXAgile Therapeutics Commends the Biden Administration's Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning ServicesGlobeNewswirePRINCETON, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today praised the Executive Order issued by President Biden that addresses barriers in access to
- 3y agoAGRXAgile Therapeutics Announces the Availability of Twirla® through FPA Women's HealthGlobeNewswireFPA Women's Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch dispensed within FPA
- 3y agoAGRXAgile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®GlobeNewswireAgile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail Channel, the
- 3y agoAGRXAgile Therapeutics Announces Closing of $7.5 Million Public OfferingGlobeNewswirePRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its
- 3y agoAGRXAgile Therapeutics Announces Pricing of $7.5 Million Public OfferingGlobeNewswirePRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its
- 3y agoAGRXAgile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate UpdateGlobeNewswireTwirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth Quarter 2022
- 3y agoAGRXAgile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023GlobeNewswirePRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close
- 3y agoAGRXAgile Therapeutics Announces Preliminary Expectations for First Quarter 2023GlobeNewswirePRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net
- 3y agoAGRXAgile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementGlobeNewswirePRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it has received a notification letter from the Listing Qualifications
- 3y agoAGRXAgile Therapeutics Announces 1-For-50 Reverse Stock SplitGlobeNewswirePRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile"), a women's healthcare company, today announced that its board of directors approved a 1-for-50 reverse stock
- 3y agoAGRXAgile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireFourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales Up 25% and 30%
- 3y agoAGRXEffects of Manual Therapy and Inclined Board Standing on Low Back Pain - NCT05780593ClinicalTrials.govNEUMERIC PAIN RATING SCALE (NPRS), Oswestry-Disability-Index (ODI), Short-form-12 questionnaire (SF-12)
- 3y agoAGRXAgile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023GlobeNewswirePRINCETON, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial results after the
- 3y agoAGRXPGCorium Pharma Solutions Names Suzanne Hinchliffe as Chief People OfficerPR NewswireAppointment of Experienced HR Executive Suzanne Hinchcliffe to Chief People Officer Continues Buildout of Experienced Leadership Team GRAND RAPIDS, Mich., March 1, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc.
- 3y agoAGRXPGCorium Pharma Solutions Names Two Industry Veterans to its Executive TeamPR NewswireAppointments of Kevin Ostrander to Chief Business Officer and Dr. Niraj Vasisht to Chief Technology Officer Further Strengthen Leadership Team GRAND RAPIDS, Mich., Feb. 9, 2023 /PRNewswire/ -- Corium Pharma Solutions,
- 3y agoAGRXAgile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline EvaluationGlobeNewswireFDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) --
- 3y agoAGRXAgile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common StockGlobeNewswirePRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a
- 3y agoAGRXGNTANMTRPGCorium Pharma Solutions Appoints Mark Sirgo as Chief Executive OfficerBusiness WireCorium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal
- 3y agoAGRXAgile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial PlanGlobeNewswireFourth Quarter 2022 Twirla Factory Sales Expected to Increase Approximately 30% from Third Quarter 2022 Full Year 2022 Factory Sales Expected to Increase Approximately 232% from Full Year 2021 Full Year 2023 Net
- 3y agoAGRXAgile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth ConferenceGlobeNewswirePRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference